There is a growing evidence for autoimmunity in acute central nervous system (CNS) disorders and treatment with therapeutic plasma exchange (TPE) may be considered. The aim was to share our experience on the clinical application of TPE in these disorders and to present a reproducible protocol which can be used even in small children.
Methods
We present a series of 8 children aged 2-12 years with transverse myelitis, Bickerstaff's brainstem encephalitis, neuromyelitis optica, and acute paraneoplastic or unspecified encephalitis in whom TPE was used as a second-line or rescue treatment.
Results
A total of 104 TPE sessions were performed where 80–110 ml/kg of plasma was exchanged using 4% albumin solution and fresh frozen plasma. Six episodes of TPE-related adverse events were documented. Fibrinogen concentrations decreased after the first TPE, whereas platelets decreased gradually. One patient died in the course of the acute illness. Three children achieved a complete resolution of symptoms, 2 children have mild sequelae; whereas 2 children remain paraplegic after a follow-up of 3 to 17 months.
Conclusions
We report 8 children with presumably autoimmune-mediated, acute CNS disorders treated with TPE as a rescue therapy. Although the effect of TPE can only be inferred, 5 children had a good clinical outcome. TPE is feasible even in small children with acute autoimmune CNS disorders.
LennonV.A., WingerchukD.M., KryzerT.J., A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis.Lancet.2004; 364(9451): 2106–2112.
2.
PröbstelA.K., DornmairK., BittnerR., Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis.Neurology.2011; 77(6): 580–588.
3.
WildemannB., JariusS.The expanding range of autoimmune disorders of the nervous system.Lancet Neurol.2013; 12(1): 22–24.
4.
BoronatA., GelfandJ.M., Gresa-ArribasN., Encephalitis and antibodies to dipeptidyl-peptidase-like protein-6, a subunit of Kv4.2 potassium channels.Ann Neurol.2013; 73(1): 120–128.
5.
Petit-PedrolM., ArmangueT., PengX., Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies.Lancet Neurol.2014; 13(3): 276–286.
6.
DalmauJ., LancasterE., Martinez-HernandezE., RosenfeldM.R., Balice-GordonR.Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis.Lancet Neurol.2011; 10(1): 63–74.
7.
de GraaffE., MaatP., HulsenboomE., Identification of delta/notch-like epidermal growth factor-related receptor as the Tr antigen in paraneoplastic cerebellar degeneration.Ann Neurol.2012; 71(6): 815–824.
8.
SchwartzJ., WintersJ.L., PadmanabhanA., Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue.J Clin Apher.2013; 28(3): 145–284.
9.
KoziolekM., MühlhausenJ., FriedeT., Therapeutic apheresis in pediatric patients with acute CNS inflammatory demyelinating disease.Blood Purif.2013; 36(2): 92–97.
10.
BigiS., BanwellB., YehE.A.Outcomes After Early Administration of Plasma Exchange in Pediatric Central Nervous System Inflammatory Demyelination.J Child Neurol.2015; 30(7): 874–880.
11.
KhuranaD.S., MelvinJ.J., KothareS.V., Acute disseminated encephalomyelitis in children: discordant neurologic and neuroimaging abnormalities and response to plasmapheresis.Pediatrics.2005; 116(2): 431–436.
12.
WrightS., HacohenY., JacobsonL., N-methyl-D-aspartate receptor antibody-mediated neurological disease: results of a UK-based surveillance study in children.Arch Dis Child.2015; 100(6): 521–526.
13.
LimM., HacohenY., VincentA.Autoimmune encephalopathies.Pediatr Clin North Am.2015; 62(3): 667–685.
14.
TenembaumS., ChitnisT., NessJ., HahnJ.S.; International Pediatric MS Study Group. Acute disseminated encephalomyelitis.Neurology.2007; 68(16 Suppl 2): S23–S36.
15.
PaglialongaF., SchmittC.P., ShroffR., Indications, technique, and outcome of therapeutic apheresis in European pediatric nephrology units.Pediatr Nephrol.2015; 30(1): 103–111.
16.
LambertC., GerickeM., SmithR., HermansC.Plasma extraction rate and collection efficiency during therapeutic plasma exchange with Spectra Optia in comparison with Hemonetics MCS+.J Clin Apher.2011; 26(1): 17–22.
17.
HequetO., StoccoV., AssariS., DrillatP., LeQ.H., KassirA., Comparison of plasma exchange performances between Spectra Optia and COBE Spectra apheresis systems in repeated procedures considering variability and using specific statistical models.Transfus Apher Sci.2014; 51(1): 47–53.
18.
LlufriuS., CastilloJ., BlancoY., Plasma exchange for acute attacks of CNS demyelination: Predictors of improvement at 6 months.Neurology.2009; 73(12): 949–953.
19.
BonnanM., ValentinoR., OlindoS., MehdaouiH., SmadjaD., CabreP.Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder.Mult Scler.2009; 15(4): 487–492.
20.
WakerleyB.R., UnciniA., YukiN., GBS Classification Group; GBS Classification Group. Guillain-Barré and Miller Fisher syndromes–new diagnostic classification.Nat Rev Neurol.2014; 10(9): 537–544.
21.
TitulerM.J., McCrackenL., GabilondoI., Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study.Lancet Neurol.2013; 12(2): 157–165.
22.
DerfussT., MeinlE.Identifying autoantigens in demyelinating diseases: valuable clues to diagnosis and treatment?Curr Opin Neurol.2012; 25(3): 231–238.
23.
DavenportA.Anticoagulation options for pediatric hemodialysis.Hemodial Int.2003; 7(2): 168–176.
24.
KreuzerM., AhlenstielT., KanzelmeyerN., EhrichJ.H., PapeL.Regional citrate anticoagulation—a safe and effective procedure in pediatric apheresis therapy.Pediatr Nephrol.2011; 26(1): 127–132.
25.
CidJ., MolinaJ.M., MustielesM.J., PerianezM., LozanoM.Comparison of plasma exchange procedures using three apheresis systems.Transfusion.2014; 55(5): 1001–1007.
26.
StegmayrB., RamlowW., BalogunR.A.Beyond dialysis: current and emerging blood purification techniques.Semin Dial.2012; 25(2): 207–213.
27.
KaraA., TurgutS., CagliA., SahinF., OranE., TuncB.Complications of therapeutic apheresis in children.Transfus Apher Sci.2013; 48(3): 375–376.
28.
HaqueA., SherG., HodaM., MoizB.Feasibility of pediatric plasma apheresis in intensive care settings.Ther Apher Dial.2014; 18(5): 497–501.
29.
SörensenJ., JarischA., SmortaC., Pediatric apheresis with a novel apheresis device with electronic interface control.Transfusion.2013; 53(4): 761–765.
30.
CherqaouiB., RouelN., AuvrignonA., Peripheral blood stem cell collection in low-weight children: retrospective comparison of two apheresis devices.Transfusion.2014; 54(5): 1371–1378.
31.
MichonB., MoghrabiA., WinikoffR., Complications of apheresis in children.Transfusion.2007; 47(10): 1837–1842.
